AstraZeneca, a global, science-led biopharmaceutical company, decided to invest around $90 million (around INR 590 crore) in near-term of five years to reinforce its manufacturing and clinical operations, along with patient safety, regulatory science, and IT services. The company has an established commitment of 40 years in India with around 4,000 employees across the departments.
This venture is believed to impact positively the AstraZeneca’s business footprint in India. The company is also committed in aligning thoroughly with vision of Indian government to generate a robust corporate, invention, and health care environment for instance “Skill India”, “National Health Policy” and “Ayushman Bharat.
“Our latest investment reflects our commitment to address the unmet needs in non-communicable diseases, enable high-value job creation and boost medical innovation in the country,” – Leon Wang, Executive VP for International Region
The manufacturing capacity at Bengaluru location is specially intended to meet international standards, in compliance to the current Good Manufacturing Practices norms of World Health Organisation (WHO). AstraZeneca as well has a considerably large clinical operation and is intensifying its international medicines development unit. Recently, the company revealed the expansion and development of its Global Technology Centre (GTC), first insourced IT facility located in Chennai, which at this time employs over 2,000 personnel’s.
Helathcare Market Research Analyst